Compare Stocks

Date Range: 

 TesaroEmergent BioSolutionsArena PharmaceuticalsHutchison China MediTechSage Therapeutics
SymbolNASDAQ:TSRONYSE:EBSNASDAQ:ARNANASDAQ:HCMNASDAQ:SAGE
Price Information
Current Price$74.96$60.85$63.07$27.09$72.07
52 Week RangeN/ABuyBuyBuyBuy
MarketRank™
Overall Score0.72.21.71.41.4
Analysis Score0.03.34.53.53.3
Community Score2.82.72.52.73.1
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.70.00.0
Earnings & Valuation Score0.63.10.00.60.6
Analyst Ratings
Consensus RecommendationN/ABuyBuyBuyBuy
Consensus Price TargetN/A$97.67$92.00$40.00$86.44
% Upside from Price TargetN/A60.50% upside45.87% upside47.66% upside19.94% upside
Trade Information
Market Cap$4.13 billion$3.27 billion$3.90 billion$3.96 billion$4.14 billion
Beta0.381.260.831.122.23
Average Volume1,970,604755,439505,698233,249496,505
Sales & Book Value
Annual Revenue$223.33 million$1.11 billion$806.43 million$204.89 million$6.87 million
Price / Sales18.482.954.7419.69612.97
CashflowN/A$2.91 per share$6.18 per shareN/AN/A
Price / CashN/A20.8910.20N/AN/A
Book Value$4.58 per share$21.08 per share$21.38 per share$2.35 per share$18.23 per share
Price / Book16.372.892.9511.533.95
Profitability
Net Income$-496,120,000.00$54.50 million$397.55 million$-106,020,000.00$-680,240,000.00
EPS($9.17)$2.91$7.69($0.80)($13.38)
Trailing P/E RatioN/A19.57N/AN/AN/A
Forward P/E RatioN/A6.61N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-295.67%12.50%N/AN/A-7,706.84%
Return on Equity (ROE)-1,209.72%26.68%-33.17%N/A-63.81%
Return on Assets (ROA)-83.34%12.70%-30.41%N/A-56.64%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.68%0.04%0.07%N/A
Current Ratio3.40%3.20%23.17%3.14%11.71%
Quick Ratio2.83%2.30%23.17%3.01%11.71%
Ownership Information
Institutional Ownership PercentageN/A80.23%89.67%33.45%N/A
Insider Ownership Percentage33.70%14.10%3.05%N/A4.80%
Miscellaneous
EmployeesN/A2,2003631,280298
Shares Outstanding55.05 million53.59 million60.59 million148.90 million58.43 million
Next Earnings DateN/A7/29/2021 (Estimated)8/4/2021 (Estimated)N/A8/9/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Declining Stock and Decent Financials: Is The Market Wrong About Sage Therapeutics, Inc. (NASDAQ:SAGE)?Declining Stock and Decent Financials: Is The Market Wrong About Sage Therapeutics, Inc. (NASDAQ:SAGE)?
nasdaq.com - May 5 at 6:08 PM
Sage Therapeutics Inc. (NASDAQ:SAGE) Forecast to gain 41.71% to hit Consensus price targetSage Therapeutics Inc. (NASDAQ:SAGE) Forecast to gain 41.71% to hit Consensus price target
marketingsentinel.com - May 5 at 1:08 PM
Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reformsPharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms
statnews.com - May 5 at 8:07 AM
Mizuho Securities Stick to Their Hold Rating for SAGE TherapeuticsMizuho Securities Stick to Their Hold Rating for SAGE Therapeutics
investing.com - May 5 at 1:14 AM
Sage Therapeutics Breaks Below 200-Day Moving Average - Notable for SAGESage Therapeutics Breaks Below 200-Day Moving Average - Notable for SAGE
nasdaq.com - May 4 at 8:14 PM
Sage braces for make-or-break depression dataSage braces for make-or-break depression data
biopharmadive.com - May 4 at 3:10 PM
Sage Therapeutics (NASDAQ:SAGE) Announces Quarterly  Earnings Results, Beats Estimates By $0.34 EPSSage Therapeutics (NASDAQ:SAGE) Announces Quarterly Earnings Results, Beats Estimates By $0.34 EPS
americanbankingnews.com - May 4 at 11:18 AM
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business ProgressSage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
finance.yahoo.com - May 4 at 10:10 AM
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue EstimatesSage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 4 at 10:10 AM
Sage Therapeutics, Inc. (NASDAQ:SAGE) Rose 65.85% From Its 52-Week Low; YTD Numbers Fall -8.96% – Here Are Some Things To Keep In MindSage Therapeutics, Inc. (NASDAQ:SAGE) Rose 65.85% From Its 52-Week Low; YTD Numbers Fall -8.96% – Here Are Some Things To Keep In Mind
marketingsentinel.com - May 1 at 6:46 PM
4. Biogen/Sage Therapeutics4. Biogen/Sage Therapeutics
fiercebiotech.com - April 28 at 9:40 AM
Sage Therapeutics to Present at Upcoming May Investor ConferencesSage Therapeutics to Present at Upcoming May Investor Conferences
finance.yahoo.com - April 28 at 9:40 AM
Bullish Prospects For Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares In 2021Bullish Prospects For Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares In 2021
stocksregister.com - April 26 at 9:09 AM
Pre-earnings Momentum Trade With a Technical Trigger in Sage Therapeutics IncPre-earnings Momentum Trade With a Technical Trigger in Sage Therapeutics Inc
cmlviz.com - April 26 at 9:09 AM
Custom Pre-earnings Bullish Diagonal Trigger in Sage Therapeutics IncCustom Pre-earnings Bullish Diagonal Trigger in Sage Therapeutics Inc
cmlviz.com - April 21 at 1:49 PM
Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
finance.yahoo.com - April 20 at 9:22 AM
SAGE Therapeutics (SAGE) Receives a Hold from Morgan StanleySAGE Therapeutics (SAGE) Receives a Hold from Morgan Stanley
smarteranalyst.com - April 19 at 7:04 PM
Morgan Stanley Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $81.00Morgan Stanley Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $81.00
americanbankingnews.com - April 19 at 1:06 PM
Analysts Say You Should Go Buying Sage Therapeutics, Inc. (NASDAQ:SAGE)Analysts Say You Should Go Buying Sage Therapeutics, Inc. (NASDAQ:SAGE)
stocksregister.com - April 18 at 8:59 AM
Is SAGE Stock A Buy or Sell?Is SAGE Stock A Buy or Sell?
finance.yahoo.com - April 14 at 3:12 PM
Sage Therapeutics (NASDAQ:SAGE) Shares Up 8%Sage Therapeutics (NASDAQ:SAGE) Shares Up 8%
americanbankingnews.com - April 14 at 1:02 PM
FY2025 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By Piper SandlerFY2025 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By Piper Sandler
americanbankingnews.com - April 14 at 10:08 AM
H.C. Wainwright Stick to Their Hold Rating for SAGE TherapeuticsH.C. Wainwright Stick to Their Hold Rating for SAGE Therapeutics
investing.com - April 14 at 12:10 AM
Sage Therapeutics (NASDAQ:SAGE) Stock Price Down 5.6%Sage Therapeutics (NASDAQ:SAGE) Stock Price Down 5.6%
americanbankingnews.com - April 13 at 3:22 PM
Sage Therapeutics and Biogens Phase 2 Study in Essential Tremor Met its Primary EndpointSage Therapeutics and Biogen's Phase 2 Study in Essential Tremor Met its Primary Endpoint
benzinga.com - April 13 at 9:09 AM
Sage Therapeutics (NASDAQ:SAGE) Coverage Initiated by Analysts at Piper SandlerSage Therapeutics (NASDAQ:SAGE) Coverage Initiated by Analysts at Piper Sandler
marketbeat.com - April 7 at 7:05 AM
DateCompanyBrokerageAction
12/9/2018TesaroSVB LeerinkBoost Price Target
12/9/2018TesaroBarclaysDowngrade
12/7/2018TesaroHC WainwrightDowngrade
12/5/2018TesaroCantor FitzgeraldDowngrade
12/4/2018TesaroEvercore ISIDowngrade
12/4/2018TesaroRoyal Bank of CanadaBoost Price Target
12/4/2018TesaroWedbushDowngrade
12/3/2018TesaroGabelliDowngrade
12/3/2018TesaroGuggenheimDowngrade
12/3/2018TesaroSunTrust BanksDowngrade
12/3/2018TesaroRobert W. BairdSet Price Target
12/3/2018TesaroWells Fargo & CompanyDowngrade
11/12/2018TesaroJefferies Financial GroupLower Price Target
11/11/2018TesaroOppenheimerSet Price Target
11/2/2018TesaroBank of AmericaBoost Price Target
11/2/2018TesaroCowenReiterated Rating
5/6/2021Emergent BioSolutionsChardan CapitalLower Price Target
5/5/2021Emergent BioSolutionsArgusDowngrade
4/30/2021Emergent BioSolutionsBenchmarkLower Price Target
9/14/2020Emergent BioSolutionsJPMorgan Chase & Co.Initiated Coverage
5/3/2021Arena PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
4/19/2021Arena PharmaceuticalsCredit Suisse GroupBoost Price Target
4/15/2021Arena PharmaceuticalsNeedham & Company LLCReiterated Rating
3/3/2021Arena PharmaceuticalsJonestradingLower Price Target
11/19/2020Arena PharmaceuticalsSmith Barney CitigroupInitiated Coverage
2/16/2021Hutchison China MediTechMizuhoInitiated Coverage
10/2/2020Hutchison China MediTechDeutsche Bank AktiengesellschaftInitiated Coverage
2/20/2020Hutchison China MediTechThe Goldman Sachs GroupInitiated Coverage
11/19/2019Hutchison China MediTechCLSAInitiated Coverage
7/5/2019Hutchison China MediTechMacquarieInitiated Coverage
3/27/2019Hutchison China MediTechHSBCInitiated Coverage
4/26/2021Sage TherapeuticsMorgan StanleyLower Price Target
4/7/2021Sage TherapeuticsPiper SandlerInitiated Coverage
2/1/2021Sage TherapeuticsRaymond JamesInitiated Coverage
1/22/2021Sage TherapeuticsBMO Capital MarketsDowngrade
12/4/2020Sage TherapeuticsWilliam BlairReiterated Rating
12/1/2020Sage TherapeuticsTruistBoost Price Target
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.